Innova Captab Q4 FY26 Results Pharma CDMO Revenue Growth and Capacity Expansion

Innova Captab Q4 results for FY26 were announced by the board of directors on 7 May 2026, with a virtual earnings call scheduled for May 8, 2026. The Innova Captab Q4 performance reflects the company’s pharmaceutical contract development and manufacturing operations serving domestic Indian pharma companies and select export markets. Through Q3 FY26, revenue stood at Rs 298 crore and the company has guided for 25% annual revenue growth as part of its Rs 300 crore capex expansion plan.

Investors tracking Innova Captab Q4 results FY26 should note that CARE Ratings reaffirmed the company’s credit rating as CARE A Positive in April 2026, reflecting its sound financial performance and growth trajectory. The Innova Captab Q4 business serves pharma companies across formulation dosage forms including tablets, capsules, and oral liquids, with an increasing focus on differentiated products and specialty generics.

Get Free Stock Recommendations on Univest

Innova Captab Q4 FY26 Results at a Glance

Track live financials and analyst ratings on the Univest Screener.

Key Highlights from Innova Captab Q4 FY26

Pharmaceutical CDMO Business Model

The Innova Captab Q4 results reflect revenues from pharmaceutical contract manufacturing for Indian branded generic companies and select exports. The Innova Captab Q4 facility at Baddi in Himachal Pradesh benefits from excise duty exemptions that enhance competitiveness for pharmaceutical manufacturing. The company produces tablets, capsules, oral liquids, and other dosage forms across multiple therapeutic segments.

Capex Expansion for Growth

The Innova Captab Q4 results are set against the backdrop of a Rs 300 crore capex program to expand pharmaceutical manufacturing capacity. This expansion, funded through a combination of term loans and internal accruals, is expected to support the 25% annual revenue growth target that management has guided. The Innova Captab Q4 CARE A Positive rating reflects lender confidence in this expansion plan.

Credit Rating Reaffirmation

The Innova Captab Q4 period saw CARE Ratings reaffirm the long-term bank facilities at CARE A Positive and short-term facilities at CARE A1, with total rated facilities enhanced to Rs 466.72 crore. The Innova Captab Q4 credit rating reaffirmation validates the company’s financial discipline and growth execution capability in the pharmaceutical CDMO space.

Risks to Monitor

• Customer concentration: Innova Captab Q4 revenues may be concentrated in a limited number of large pharmaceutical company customers, creating dependency risk.
• Regulatory compliance: CDSCO inspections and drug quality standards compliance are critical for Innova Captab Q4 operations, with any recall or warning letter creating significant disruption.
• Capacity utilisation post-capex: The Rs 300 crore capex needs to be filled with customer orders promptly to justify the investment and avoid earnings dilution during the ramp-up period.
• Baddi excise benefit continuation: Any policy change affecting the excise duty exemptions at Baddi would increase production costs and reduce Innova Captab Q4 competitive advantage.

Conclusion

The Innova Captab Q4 results FY26 reflect a pharmaceutical CDMO company on a strong growth trajectory, with Q3 FY26 revenue at Rs 298 crore, a 25% growth target for FY27, and a Rs 300 crore capex expansion plan underway. The Innova Captab Q4 CARE A Positive rating reaffirmation provides confidence in execution.

For FY27, the most important variable for Innova Captab Q4 investors is whether the Rs 300 crore capacity expansion is commissioned on schedule and whether the new capacity can be filled quickly through existing and new customer relationships to justify the capital investment within a reasonable payback period.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

What does Innova Captab do?

Innova Captab Q4 is a pharmaceutical contract development and manufacturing organisation that produces tablets, capsules, and oral liquids for branded generic pharmaceutical companies in India and export markets.

When were Innova Captab Q4 FY26 results announced?

Innova Captab Q4 FY26 results were announced by the board on 7 May 2026. A virtual earnings call was scheduled for 8 May 2026 at 11 AM IST for detailed management commentary.

What is Innova Captab’s revenue growth target?

Innova Captab Q4 management has guided for 25% annual revenue growth, supported by a Rs 300 crore capacity expansion plan at its pharmaceutical manufacturing facilities in Baddi, Himachal Pradesh.

What is the CARE rating for Innova Captab?

CARE Ratings reaffirmed Innova Captab’s long-term bank facilities at CARE A Positive and short-term facilities at CARE A1 in April 2026, reflecting strong financial performance and growth trajectory.

What is Innova Captab Q4 FY27 outlook?

Innova Captab Q4 FY27 depends on the Rs 300 crore capacity expansion timeline, customer order book additions, and whether the CDMO revenue growth rate can sustain at 25% annually as guided by management.

Recent Article

Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026